Remove Biochemical Assays Remove Disease Remove Therapies
article thumbnail

#WhyIScienceQ&A: A neuroscientist advocates for stepping outside your comfort zone in research

Broad Institute

By Allessandra DiCorato June 16, 2025 Credit: Allison Colorado, Broad Communications Giulia Monti studies Alzheimer's disease in the lab of Anna Greka. She had spent the last four years earning her PhD at Aarhus University in Denmark, studying proteins called cargo receptors in Alzheimer’s disease. What got you interested in research?

article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SARS-CoV-2 main protease. Crowdsourcing, peptidomimetics and fragments

Molecular Design

While I’m not particularly keen on the use of the term ‘open source’ in this context, I have absolutely no quibble with the goal of seeking cures and treatments for diseases that are ignored by commercial drug discovery organizations.

article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue. How does “potency” apply to cell and gene therapy (CGT) products?